MED

NYSE

MEDIFAST INC

SectorConsumer StaplesIndustryPackaged Foods

$10.96+0.02 (+0.14%)

News25/Ratings7

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific. It offers bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by Take Shape for Life, and Flavors of Home brands. The company markets its products through point of sale transactions over ecommerce platform and its franchisee system. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

News · 26 weeks26-57%

2025-10-262026-04-19

Mix1690d

SEC Filings5(31%)
Other4(25%)
Insider4(25%)
Earnings3(19%)

Latest news

25 items

3dPR
Medifast to Announce Financial Results for the First Quarter Ended March 31, 2026
Medifast (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter ended March 31, 2026 on Monday, May 4, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on May 4, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www.MedifastInc.com or
17dSEC
SEC Form DEF 14A filed by MEDIFAST INC
DEF 14A - MEDIFAST INC (0000910329) (Filer)
17dSEC
SEC Form DEFA14A filed by MEDIFAST INC
DEFA14A - MEDIFAST INC (0000910329) (Filer)
27dINSIDER
SEC Form 3 filed by new insider Johnson Nicholas Mark
3 - MEDIFAST INC (0000910329) (Issuer)
27dINSIDER
SEC Form 4 filed by Mackenzie Jonathan Barrett
4 - MEDIFAST INC (0000910329) (Issuer)
27dINSIDER
SEC Form 4 filed by Maloney James P.
4 - MEDIFAST INC (0000910329) (Issuer)
27dINSIDER
SEC Form 4 filed by Chard Daniel R
4 - MEDIFAST INC (0000910329) (Issuer)
27dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by MEDIFAST INC
SCHEDULE 13G/A - MEDIFAST INC (0000910329) (Subject)
34dSEC
MEDIFAST INC filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
8-K - MEDIFAST INC (0000910329) (Filer)
34dPR
Medifast Announces Cooperation Agreement with Steamboat Capital
Company Agrees to Nominate Parsa Kiai and Jeff Rose as Director Candidates at 2026 Annual Meeting of Stockholders Medifast, Inc. (NYSE:MED), the metabolic health and wellness company known for its science-backed, coach-guided lifestyle system, today announced the company's Board of Directors has agreed to nominate Parsa Kiai and Jeff Rose from Steamboat Capital Partners LLC as independent director candidates to stand for election at the company's 2026 Annual Meeting of Stockholders, which is provisionally scheduled for May 19, 2026. These nominations are pursuant to a Cooperation Agreement entered into between the company and Steamboat Capital, which beneficially owns above 5% of the comp
62dPR
Scientific Evidence Demonstrates OPTAVIA®'s Metabolic Health Benefits, Opening the Door to Qualified HSA/FSA Clients
As part of its continued focus on improving metabolic health, Medifast® (NYSE:MED) today announced that OPTAVIA's comprehensive metabolic health system is available for reimbursement on select insurance plans using Health Savings Accounts (HSA) and Flexible Spending Accounts (FSA). OPTAVIA clients may be able to save up to 40% on program costs by working with their medical provider and insurance administrator to use pre-tax medical funds, offering accessibility for those prioritizing their metabolic health. This milestone reinforces Medifast's position as a science-driven health and wellness leader, with a metabolic reset plan that reverses metabolic dysfunction — a widespread but often o
65dSEC
SEC Form 10-K filed by MEDIFAST INC
10-K - MEDIFAST INC (0000910329) (Filer)
65dSEC
MEDIFAST INC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - MEDIFAST INC (0000910329) (Filer)
65dPR
Medifast Announces Fourth Quarter and Full Year 2025 Financial Results
Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the fourth quarter and full year ended December 31, 2025. Fourth Quarter 2025 Revenue of $75.1 million, with revenue per active earning coach of $4,664 Independent active earning coaches of 16,100 Net loss of $18.1 million, or $1.65 per diluted share ("EPS"), which includes the tax provision charge to establish a non-cash valuation allowance on the Company's deferred tax balance of $12.1 million (or $1.10 per diluted share) Cash, cash equivalents, and investment Securities of $167.3 million and no debt Full Year 2025 Revenue of $385
70dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by MEDIFAST INC
SCHEDULE 13G/A - MEDIFAST INC (0000910329) (Subject)
79dPR
Medifast to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2025
Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, will announce financial results for the quarter and full year ended December 31, 2025 on Tuesday, February 17, 2026, after market close. The Company will host a conference call to discuss the results with additional comments and details. Company participants will be Dan Chard, Chairman and Chief Executive Officer, Nick Johnson, President, and Jim Maloney, Chief Financial Officer. The conference call is scheduled to begin at 4:30 p.m. ET on February 17, 2026. The call will be broadcast live over the Internet, hosted on the Investor Relations section of Medifast's website at www
94dPR
The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings
ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC. Baystreet.ca News Commentary VANCOUVER, BC, Jan. 19, 2026 /PRNewswire/ -- The global consumer healthcare market is hitting a massive structural wall, projected to reach $362.17 billion in 2026[1]. In this high-stakes environment, commercial survival is no longer just about the product; it hinges on precision regulatory execution. Eight key regulatory and compliance pressures[2] are reshaping sector strategy, forcing a capital rotation into a first-mover cohort that includes Doseology Sciences Inc. (CSE:MOOD) (OTCPK:DOSEF) (FSE: VU70), Philip Morris (NYSE:PM), Celsius Holdings (NASDAQ:CELH), USANA Health Sciences (NYSE:USNA), and Medifast (NYSE:MED
108dSEC
MEDIFAST INC filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
8-K - MEDIFAST INC (0000910329) (Filer)
108dPR
Medifast Announces Planned Leadership Transition
Nicholas Johnson Appointed President, and Expected to Succeed Dan Chard as CEO in June 2026; Chard to Remain Chairman Medifast, Inc. (NYSE:MED) today announced a planned leadership transition designed to provide continuity and stability as the company continues its evolution toward metabolic health. Medifast Chairman & Chief Executive Officer Dan Chard has informed the Board of Directors that he plans to step down as Chief Executive Officer in June 2026. Chard will continue to serve as Chairman of the Board following the transition. The Board has appointed Medifast's Chief Field Operations Officer Nicholas Johnson as President of Medifast, effective immediately. Johnson will work clo
135dPR
OPTAVIA Survey Reveals 80% of Americans Lack Understanding of Metabolic Health Despite Its Major Impact to Overall Health and Wellbeing
Findings underscore critical gaps in awareness, fueling demand for evidence-based solutions to improve energy, sleep, weight management and other key health markers OPTAVIA, the science-backed, coach-guided lifestyle system, announced a new report "Metabolic Health in America: Awareness, Attitudes and Action." The report includes findings based on an online survey conducted by OPTAVIA with KRC Research among a nationally representative group of U.S. adults ages 18–75, recruited to match U.S. Census demographics*. The data highlights a pressing concern: 80% of American adults lack understanding of metabolic health, yet many are experiencing the consequences of poor metabolic health - such a
161dPR
Medifast Scientific & Clinical Affairs Team Showcases New Research in Metabolic Health at ObesityWeek Conference
Company's Clinical Heritage and Leadership in Metabolic Health Highlighted Through Poster Presentations and Expert Contributions Medifast, the health and wellness company known for its science-backed, coach-guided lifestyle system, continues to lead the charge in addressing the growing health crisis of metabolic dysfunction by unveiling new research findings during ObesityWeek. Hosted by The Obesity Society in Atlanta, Georgia November 4–7, 2025, the annual conference for obesity researchers and clinicians centers on the latest developments in evidence-based obesity science: cutting-edge basic and clinical research, state-of-the-art obesity treatment and prevention and the latest efforts
161dSEC
SEC Form SCHEDULE 13G filed by MEDIFAST INC
SCHEDULE 13G - MEDIFAST INC (0000910329) (Subject)
171dSEC
SEC Form 10-Q filed by MEDIFAST INC
10-Q - MEDIFAST INC (0000910329) (Filer)
171dSEC
MEDIFAST INC filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - MEDIFAST INC (0000910329) (Filer)
171dPR
Medifast Announces Third Quarter 2025 Financial Results
Medifast (NYSE:MED), the health and wellness company known for its science-backed, coach-guided lifestyle system, today reported results for the third quarter ended September 30, 2025. Third Quarter 2025 Revenue: $89.4 million, with revenue per active earning coach of $4,585 Active Coaches: Independent active earning OPTAVIA® coaches of 19,500 Net Loss: $2.3 million or $0.21 loss per diluted share Strong Balance Sheet: $173.5 million in cash, cash equivalents, and investment securities with no debt "We're transforming Medifast from a weight-loss company into a leader in promoting metabolic health," said Dan Chard, Chairman and Chief Executive Officer of Medifast. "Our clini